Articles On Patrys (ASX:PAB)

Patrys (PAB) receives $250,000 in funding to support its research on treatments for brain cancer The Cure Brain Cancer Foundation allocated the funds to Patrys’ collaborator, Telethon Kids Institute The money will be used to identify poten...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Therapeutic antibody development company Patrys (ASX:PAB) has identified and selected an optimised stable cell line for the production of its full-sized IgG deoxymab, PAT-DX3.

Therapeutic antibody development company Patrys (PAB) identifies and selects an optimised stable cell line for production of its PAT-DX3 antibody The company says establishing the stable cell line for the production of PAT-DX3 has come ahe...

“With this key reagent now identified and in hand, we can rapidly move into developing a commercial-scale production process to support both the clinical and partnering opportunities we have for PAT-DX3,” says CEO & MD.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

In a newsletter on Tuesday, CEO and managing director Dr James Campbell outlined the growing upside in the ADC space — and how Patrys is poised to capitalise on momentum.

The S&P/ASX200 climbed into the close on Tuesday. Most of the 35 or so point gain (0.5%)  comes off the back of some good, steady central banking, delivered – nay, telegraphed – at 2.30pm when the Reserve Bank (RBA) left the cash rate a...

When markets get the jitters, smaller companies are often in the firing line and ASX microcaps have copped the brunt of the impact from last week’s global stock selloff. The composite microcap Emerging Companies index slumped by more than 3...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

The company's wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has also received a $1,188,581 R&D Tax Incentive Refund for the 2020/2021 financial year.

Patrys (PAB) completes the first engineering run of its cancer antibody candidate, PAT-DX1, resulting in a lower drug product recoveries than expected The product yield from the fermentation process was consistent with the small scale pilo...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ‘Covid-induced trial, interrupted syndrome’ is no more apparent than within the walls of Imagion’s (ASX:IBX) San Diego headquarters, where the company is spearheading a new form of diagnostic imaging based on pin-pointed magnetic target...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

“Having two assets on the path to the clinic is a very exciting place to be, and makes Patrys a much more robust investment opportunity. I personally can’t wait to see what we learn and I encourage you to stay tuned for our updates," says C...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

“Based on the promising data we have seen for PAT-DX3 since we announced it 12 months ago, we believe there are a range of very attractive potential applications for this deoxymab that will significantly expand opportunities for internal de...

The ASX 200 Health Index (XHJ) is up by 1.30% at the time of writing, compared to the broader index which is higher by 0.5%. The US FDA has accepted the New Drug Application (NDA) for Maxigesic IV, AFT Pharma’s (ASX:AFP) intravenous form of...

Patrys (PAB) will be undertaking a $7.8 million capital raising, consisting of a placement and a fully-underwritten rights issue The placement will issue more than 71.4 million shares to institutional investor Territory Funds Management to...

After a positive Monday to Thursday, the ASX wiped out gains made across the week, losing more than 1% today The ASX followed a plunge on Wall Street with the ASX 200 closing at 7,324, which was 1.44% lower than yesterday’s close. While Wal...

Local stocks lost ground on Thursday, with minor falls at the big end of town and a slightly steeper drop of ~0.8% for the microcap Emerging Markets Index. The ASX opened with a weak lead from Wall Street, after a fortnight of steady gains...

“This quarter has delivered a period of significant momentum for Patrys. We have continued to build the portfolio of data for deoxymabs which has further expanded the broad and promising utility for our antibody assets in addition to meetin...

Patrys (ASX:PAB) has announced data from its completed pre-clinical study that has demonstrated that its full-sized deoxymab antibody, PAT-DX3, can be used as a targeting agent for antibody-drug conjugates to deliver anti-cancer dru...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours where they can inhibit tumour growth and improve survival," says CEO.

Patrys (PAB) has shown its antibody can be used as a targeting agent to deliver anti-cancer drugs to tumours A recently completed pre-clinical study demonstrated mice treated with the company’s full-sized deoxymab antibody, PAT-DX3, showed...

Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers.

Its primary focus is to move its lead asset, PAT DX1, a small antibody fragment, to the first human clinical trial and it is confident of hitting this milestone in late 2022. 

Its primary focus is to move its lead asset, PAT DX1, a small antibody fragment, to the first human clinical trial and it is confident of hitting this milestone in late 2022. 

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Local stocks lost ground on Thursday as a tone of caution emerged in Asian trade, ahead of the US Federal Reserve’s annual symposium, which is set to kick off on Friday night. The ASX 200 finished 0.54% lower and in a theme that has held co...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The ASX closed in negative territory despite a solid gain in tech stocks. The ASX 200 closed 0.23% down at 7,474 points although the ASX Emerging Companies Index rose 1.06% to close at 2,226 points. Despite tech stocks gaining 4.38%, as inv...

Patrys Limited (ASX: PAB) shares are tumbling in late morning trade. At the time of writing, the Patrys share price has slumped 16.33% following the company’s latest announcement. Below we take a look at the ASX healthcare company’s update...

ASX 200 health stocks index fell by 0.12% this morning, compared to the broader index which fell by 0.19%. A class action proceeding against Mayne Pharma (ASX:MYX) has been brought by Phi Finney McDonald on behalf on investors who bought MY...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...